ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 72 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $751,355 | -34.8% | 124,191 | -16.4% | 0.00% | – |
| Q2 2023 | $1,152,989 | +115.1% | 148,581 | +58.0% | 0.00% | – |
| Q1 2023 | $535,965 | +58.0% | 94,029 | +63.3% | 0.00% | – |
| Q4 2022 | $339,118 | +180.3% | 57,575 | +52.8% | 0.00% | – |
| Q3 2022 | $121,000 | -65.8% | 37,690 | -52.4% | 0.00% | – |
| Q2 2022 | $354,000 | -9.5% | 79,203 | +8.2% | 0.00% | – |
| Q1 2022 | $391,000 | -42.6% | 73,197 | +57.9% | 0.00% | – |
| Q4 2021 | $681,000 | +72.0% | 46,367 | +145.1% | 0.00% | – |
| Q3 2021 | $396,000 | -84.7% | 18,914 | -87.0% | 0.00% | – |
| Q2 2021 | $2,582,000 | +717.1% | 146,015 | +1033.2% | 0.00% | – |
| Q1 2021 | $316,000 | -70.1% | 12,885 | -58.7% | 0.00% | – |
| Q4 2020 | $1,056,000 | +4491.3% | 31,209 | +3223.6% | 0.00% | – |
| Q3 2020 | $23,000 | -76.0% | 939 | -67.1% | 0.00% | – |
| Q2 2020 | $96,000 | – | 2,853 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |